Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Inclusion Criteria: * Male or female, at least 18 years of age. * Ability to comprehend the study procedures and signed informed consent. * If pre-menopausal female, must have a negative serum pregnancy test, and, if of child bearing potential, must be using an acceptable method of contraception. * Diagnosed with any the following: acute leukemia (ALL or AML), chronic leukemia (CML, CLL, CMML, or hairy cell leukemia), myelodysplasia, aplasia, hematopoietic or non-hematopoietic solid tumor, or therapy (chemotherapy or radiation) induced bone marrow aplasia or hypoplasia. Either autologous or allogeneic bone marrow transplant or peripheral or cord blood stem cell recipients may be enrolled. * WHO grade 2 or greater bleeding. Exclusion Criteria: * Acute or chronic DIC as evidence by D-dimer greater than 8 μg/mL and fibrinogen less than 100 mg (0.1 g)/dL. Both criteria must be met. If data are in the medical record for fibrin degradation products (FDPs), then FDP must be \<=40 μg/mL (FDP \>40 μg/mL is indicative of DIC). * PT or aPTT \> 1.3 times the upper limit of normal for the laboratory. * History of major operative procedures that required general anesthesia in the past 2 weeks. * History of any prior major unprovoked thrombotic events and/or known inherited disorder of coagulation or platelet function (by history) (not to include clots in catheters, etc). * A history or diagnosis of immune thrombocytopenia, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrom…